6 Parkway North
Tel: 224-507-1000 and (866) 337-6996
At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Headquartered in Copenhagen with a U.S. home office in Deerfield, Ill., Lundbeck is the only global biopharmaceutical company focused solely on brain diseases. Our legacy in neuroscience goes back seven decades and we have a long heritage of innovation. Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for psychiatric and neurological disorders. Today, we remain uncompromisingly committed to improving the quality of life for people impacted by brain disorders. Lundbeck is unique from other biopharmaceutical companies in that we are 70 percent owned by a research-focused foundation. We have a deep and productive pipeline, and we continue to bring forward symptomatic therapies to help people live better lives, while simultaneously pursuing disease-modifying treatments.
Offices in :
Deerfield, IL - Lundbeck US Home Office
LaJolla, CA - Lundbeck La Jolla Research Center, Inc.
Bothell, WA - Lundbeck Seattle BioPharmaceuticals, Inc
Stock Exchange: Copenhagen
Stock Symbol: LUN.CO
What Makes Lundbeck a Top Workplace?”
193 articles with Lundbeck
Lundbeck announced new data from an oral abstract for VYEPTI®, along with three poster presentations, are being presented at the 2022 Annual Scientific Meeting of the American Academy of Neurology, which is being held in person from April 2-7 and virtually from April 24-26.
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
It's been a week of gained and lost opportunities after two large biopharmaceutical firms announced changes to their staff rosters.
4/21/2021The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
8/10/2020It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
AHS Posters for Lundbeck’s VYEPTI™ (eptinezumab-jjmr) in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache
Post-hoc closed testing analysis suggests onset of a migraine preventive effect with intravenous VYEPTI as early as day 1 following the initial dose
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
AllianceRx Walgreens Prime one of only two specialty pharmacies to distribute Vyepti™, the first and only intravenous preventive treatment for migraine
New medicine one of several limited distribution drugs available through specialty pharmacy
4/9/2020Biopharma companies from across the globe provide updates to their business operations and pipelines.
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds The PROMISE 2 study met its primary endpoint, with VYEPTI demonstrating statistically significant reductions in mean monthly migraine days (MMD) after the first dose over months 1-3 The preventive effects of VYEPTI were demonstrated as early as day 1 post-infusion and sustained thro
FDA Approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – The First and Only Intravenous Preventive Treatment for Migraine
In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), VYEPTI met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Lundbeck selects Discngine’s 3decision® platform to leverage complex protein-ligand 3D structure data in the discovery of new treatments for brain diseases
Discngine announces that Lundbeck has selected its proprietary 3decision® collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.
Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.
Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research
Collaboration sets out to identify potential treatment candidates for disorders of the central nervous system including depression, psychosis, seizure and neurodegenerative disorders.